{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:52:21Z","timestamp":1776066741085,"version":"3.50.1"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02367-3","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:14:19Z","timestamp":1776064459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Emir","family":"Muzurovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Ze\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri P","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"2","key":"2367_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa2415879","volume":"393","author":"C Magnussen","year":"2025","unstructured":"Global Cardiovascular Risk Consortium, Magnussen C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, Aviles-Santa L, Bakker SJL, et al. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. N Engl J Med. 2025;393(2):125\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2415879.","journal-title":"N Engl J Med"},{"key":"2367_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/cells13171471","volume":"13","author":"VR Netala","year":"2024","unstructured":"Netala VR, Teertam SK, Li H, Zhang Z. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells. 2024;13:1471. https:\/\/doi.org\/10.3390\/cells13171471.","journal-title":"Cells"},{"key":"2367_CR3","doi-asserted-by":"publisher","first-page":"sfaf260","DOI":"10.1093\/ckj\/sfaf260","volume":"18","author":"F Moncho","year":"2025","unstructured":"Moncho F, Benlloch S, G\u00f3rriz JL. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Clin Kidney J. 2025;18:sfaf260. https:\/\/doi.org\/10.1093\/ckj\/sfaf260.","journal-title":"Clin Kidney J"},{"issue":"9","key":"2367_CR4","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/biomedicines13092162","volume":"13","author":"MDRM Souto Maior","year":"2025","unstructured":"Souto Maior MDRM, Ribeiro NLI, Silva HVV, Lopes EP, Costa EC. Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review. Biomedicines. 2025;13(9):2162. https:\/\/doi.org\/10.3390\/biomedicines13092162.","journal-title":"Biomedicines"},{"key":"2367_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5009\/gnl240407","volume":"19","author":"Y Pei","year":"2025","unstructured":"Pei Y, Goh GB-B. Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease. Gut Liver. 2025;19:8\u201318. https:\/\/doi.org\/10.5009\/gnl240407.","journal-title":"Gut Liver"},{"key":"2367_CR6","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/ijms26115164","volume":"26","author":"T Kanda","year":"2025","unstructured":"Kanda T, Sasaki-Tanaka R, Abe H, Kimura N, Yoshida T, Hayashi K, et al. Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review. Int J Mol Sci. 2025;26:5164. https:\/\/doi.org\/10.3390\/ijms26115164.","journal-title":"Int J Mol Sci"},{"key":"2367_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"2367_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/kisup.2012.64","volume":"3","author":"Chapter 1","year":"2013","unstructured":"Chapter 1. Definition and classification of CKD. Kidney Int Suppl Elsevier. 2013;3:19\u201362. https:\/\/doi.org\/10.1038\/kisup.2012.64.","journal-title":"Kidney Int Suppl Elsevier"},{"issue":"6","key":"2367_CR9","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168\u201385. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2367_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645\u201362. https:\/\/doi.org\/10.1016\/j.molmed.2015.08.005.","journal-title":"Trends Mol Med"},{"key":"2367_CR11","doi-asserted-by":"publisher","first-page":"1539283","DOI":"10.3389\/fmed.2025.1539283","volume":"12","author":"Z Gao","year":"2025","unstructured":"Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med (Lausanne). 2025;12:1539283. https:\/\/doi.org\/10.3389\/fmed.2025.1539283.","journal-title":"Front Med (Lausanne)"},{"key":"2367_CR12","doi-asserted-by":"publisher","unstructured":"M\u00f8ller S, Kimer N, Hove JD, Barl\u00f8se M, Gluud LL. Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects. Eur J Prev Cardiol. 2025;zwae306. https:\/\/doi.org\/10.1093\/eurjpc\/zwae306.","DOI":"10.1093\/eurjpc\/zwae306"},{"key":"2367_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.015","author":"GBD 2023 Cardiovascular Disease Collaborators","year":"2025","unstructured":"GBD 2023 Cardiovascular Disease Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990\u20132023. J Am Coll Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.015. S0735-1097(25)07428-5.","journal-title":"J Am Coll Cardiol"},{"key":"2367_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/CIRCULATIONAHA.122.062457","volume":"147","author":"H Ma","year":"2023","unstructured":"Ma H, Wang X, Xue Q, Li X, Liang Z, Heianza Y, et al. Cardiovascular Health and Life Expectancy Among Adults in the United States. Circulation. 2023;147:1137\u201346. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062457.","journal-title":"Circulation"},{"issue":"10518","key":"2367_CR15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"PB Mark","year":"2025","unstructured":"Mark PB, Stafford LK, Grams ME, Aalruz H, ElHafeez SA, Abdelgalil AA, et al. Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10518):2461\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(25)01853-7.","journal-title":"Lancet"},{"key":"2367_CR16","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.29546","volume":"67","author":"AM Allen","year":"2018","unstructured":"Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study. Hepatology. 2018;67:1726\u201336. https:\/\/doi.org\/10.1002\/hep.29546.","journal-title":"Hepatology"},{"key":"2367_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","volume":"21","author":"CH Ng","year":"2023","unstructured":"Ng CH, Lim WH, Lim GEH, Tan DJH, Syn N, Muthiah MD, et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21:931\u2013e9395. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.014.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2367_CR18","doi-asserted-by":"publisher","first-page":"101898","DOI":"10.1016\/j.aohep.2025.101898","volume":"30","author":"C Kan","year":"2025","unstructured":"Kan C, Zhang K, Wang Y, Zhang X, Liu C, Ma Y. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990\u20132021 to 2045. Ann Hepatol. 2025;30(2):101898. https:\/\/doi.org\/10.1016\/j.aohep.2025.101898.","journal-title":"Ann Hepatol"},{"key":"2367_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"C Magnussen","year":"2023","unstructured":"Global Cardiovascular Risk Consortium, Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023;389:1273\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2206916.","journal-title":"N Engl J Med"},{"key":"2367_CR20","doi-asserted-by":"publisher","first-page":"e028762","DOI":"10.1161\/JAHA.122.028762","volume":"12","author":"X Peng","year":"2023","unstructured":"Peng X, Jin C, Song Q, Wu S, Cai J. Stage 1 Hypertension and the 10-Year and Lifetime Risk of Cardiovascular Disease: A Prospective Real\u2010World Study. J Am Heart Assoc. 2023;12:e028762. https:\/\/doi.org\/10.1161\/JAHA.122.028762.","journal-title":"J Am Heart Assoc"},{"key":"2367_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(21)00590-0.","journal-title":"Lancet"},{"key":"2367_CR22","doi-asserted-by":"publisher","first-page":"948707","DOI":"10.3389\/fcvm.2022.948707","volume":"9","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Gao X, Jia H-Y, Li F-R, Ye H. Influence of hypertension duration and blood pressure levels on cardiovascular disease and all-cause mortality: A large prospective cohort study. Front Cardiovasc Med. 2022;9:948707. https:\/\/doi.org\/10.3389\/fcvm.2022.948707.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2367_CR23","doi-asserted-by":"publisher","first-page":"A216","DOI":"10.18332\/tid\/141425","volume":"19","author":"CP Wen","year":"2021","unstructured":"Wen CP, Lu PJ, Gao W, Lee JH. The cardiovascular disease risk of hypertensive smokers. Tob Induc Dis. 2021;19(1):A216. https:\/\/doi.org\/10.18332\/tid\/141425.","journal-title":"Tob Induc Dis"},{"key":"2367_CR24","doi-asserted-by":"publisher","first-page":"1503837","DOI":"10.3389\/fpubh.2025.1503837","volume":"13","author":"Y Lai","year":"2025","unstructured":"Lai Y, Long H, Liang Z, Wu C, Wu L, Liu C, et al. Global burden and risk factors of chronic kidney disease due to hypertension in adults aged 20 plus years, 1990\u20132021. Front Public Health. 2025;13:1503837. https:\/\/doi.org\/10.3389\/fpubh.2025.1503837.","journal-title":"Front Public Health"},{"key":"2367_CR25","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/s41440-025-02188-x","volume":"48","author":"KS Liu","year":"2025","unstructured":"Liu KS, Wang B, Mak IL, Choi EP, Lam CL, Wan EY. Early onset of hypertension and increased relative risks of chronic kidney disease and mortality: two population-based cohort studies in United Kingdom and Hong Kong. Hypertens Res. 2025;48:1963\u201371. https:\/\/doi.org\/10.1038\/s41440-025-02188-x.","journal-title":"Hypertens Res"},{"key":"2367_CR26","doi-asserted-by":"publisher","first-page":"1426953","DOI":"10.3389\/fcvm.2024.1426953","volume":"11","author":"L Qiu","year":"2024","unstructured":"Qiu L, Wu B. The relationship between the age of onset of hypertension and chronic kidney disease: a cross-sectional study of the American population. Front Cardiovasc Med. 2024;11:1426953. https:\/\/doi.org\/10.3389\/fcvm.2024.1426953.","journal-title":"Front Cardiovasc Med"},{"key":"2367_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1\u201387. https:\/\/doi.org\/10.1016\/j.kint.2020.11.003.","journal-title":"Kidney Int"},{"key":"2367_CR28","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1097\/HJH.0000000000002927","volume":"39","author":"M Zhuo","year":"2021","unstructured":"Zhuo M, Yang D, Goldfarb-Rumyantzev A, Brown RS. The Association of Systolic Blood Pressure with Mortality in Patients with Stage 1\u20134 Chronic Kidney Disease. J Hypertens. 2021;39:2250\u20137. https:\/\/doi.org\/10.1097\/HJH.0000000000002927.","journal-title":"J Hypertens"},{"key":"2367_CR29","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"AK Cheung","year":"2017","unstructured":"Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol. 2017;28:2812\u201323. https:\/\/doi.org\/10.1681\/ASN.2017020148.","journal-title":"J Am Soc Nephrol"},{"key":"2367_CR30","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","volume":"177","author":"R Malhotra","year":"2017","unstructured":"Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. JAMA Intern Med. 2017;177:1498\u2013505. https:\/\/doi.org\/10.1001\/jamainternmed.2017.4377.","journal-title":"JAMA Intern Med"},{"key":"2367_CR31","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1681\/ASN.2017010040","volume":"28","author":"E Ku","year":"2017","unstructured":"Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, et al. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017;28:2794\u2013801. https:\/\/doi.org\/10.1681\/ASN.2017010040.","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"2367_CR32","doi-asserted-by":"publisher","first-page":"02453","DOI":"10.1016\/j.jhep.2025.08.017","volume":"S0168\u20138278","author":"XD Zhou","year":"2025","unstructured":"Zhou XD, Lian LY, Chen QF, Kim SU, Cheuk-Fung Yip T, Petta S, et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol. 2025;S0168\u20138278(25):02453\u20135. https:\/\/doi.org\/10.1016\/j.jhep.2025.08.017.","journal-title":"J Hepatol"},{"key":"2367_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S2213-8587(23)00223-1","volume":"11","author":"S Kaptoge","year":"2023","unstructured":"Kaptoge S, Seshasai SRK, Sun L, Walker M, Bolton T, Spackman S, et al. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol. 2023;11:731\u201342. https:\/\/doi.org\/10.1016\/S2213-8587(23)00223-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2367_CR34","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.numecd.2023.04.003","volume":"33","author":"YV Chudasama","year":"2023","unstructured":"Chudasama YV, Khunti K, Coles B, Gillies CL, Islam N, Rowlands AV, et al. Life expectancy following a cardiovascular event in individuals with and without type 2 diabetes: A UK multi-ethnic population-based observational study. Nutr Metab Cardiovasc Dis. 2023;33:1358\u201366. https:\/\/doi.org\/10.1016\/j.numecd.2023.04.003.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2367_CR35","doi-asserted-by":"publisher","first-page":"e031095","DOI":"10.1161\/JAHA.123.031095","volume":"13","author":"S Butalia","year":"2024","unstructured":"Butalia S, Chu LM, Dover DC, Lau D, Yeung RO, Eurich DT, et al. Association Between Hemoglobin A1c and Development of Cardiovascular Disease in Canadian Men and Women Without Diabetes at Baseline: A Population-Based Study of 608 474 Adults. J Am Heart Assoc. 2024;13:e031095. https:\/\/doi.org\/10.1161\/JAHA.123.031095.","journal-title":"J Am Heart Assoc"},{"key":"2367_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9.","journal-title":"Lancet"},{"issue":"1","key":"2367_CR37","doi-asserted-by":"publisher","first-page":"e001928","DOI":"10.1136\/bmjdrc-2020-001928","volume":"9","author":"HKR Riise","year":"2021","unstructured":"Riise HKR, Igland J, Sulo G, Graue M, Haltbakk J, Tell GS, et al. Casual blood glucose and subsequent cardiovascular disease and all-cause mortality among 159 731 participants in Cohort of Norway (CONOR). BMJ Open Diabetes Res Care. 2021;9(1):e001928. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001928.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2367_CR38","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41440-024-02054-2","volume":"48","author":"T Okura","year":"2025","unstructured":"Okura T. The importance of the time in target range (TTR) of glucose and blood pressure. Hypertens Res. 2025;48:1218\u201320. https:\/\/doi.org\/10.1038\/s41440-024-02054-2.","journal-title":"Hypertens Res"},{"key":"2367_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. Adv Chronic Kidney Dis. 2018;25:121\u201332. https:\/\/doi.org\/10.1053\/j.ackd.2017.10.011.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2367_CR40","doi-asserted-by":"publisher","first-page":"1513008","DOI":"10.3389\/fendo.2025.1513008","volume":"16","author":"X Ma","year":"2025","unstructured":"Ma X, Liu R, Xi X, Zhuo H, Gu Y. Global burden of chronic kidney disease due to diabetes mellitus, 1990\u20132021, and projections to 2050. Front Endocrinol (Lausanne). 2025;16:1513008. https:\/\/doi.org\/10.3389\/fendo.2025.1513008.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2367_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302\u20138. https:\/\/doi.org\/10.1681\/ASN.2012070718.","journal-title":"J Am Soc Nephrol"},{"key":"2367_CR42","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(12)61350-6.","journal-title":"Lancet"},{"key":"2367_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jval.2015.10.010","volume":"19","author":"A Hayes","year":"2016","unstructured":"Hayes A, Arima H, Woodward M, Chalmers J, Poulter N, Hamet P, et al. Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value Health. 2016;19:36\u201341. https:\/\/doi.org\/10.1016\/j.jval.2015.10.010.","journal-title":"Value Health"},{"key":"2367_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","volume":"92","author":"CP Wen","year":"2017","unstructured":"Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92:388\u201396. https:\/\/doi.org\/10.1016\/j.kint.2017.01.030.","journal-title":"Kidney Int"},{"key":"2367_CR45","doi-asserted-by":"publisher","first-page":"22232","DOI":"10.1038\/s41598-024-72795-0","volume":"14","author":"Z Yang","year":"2024","unstructured":"Yang Z, Li A, Jiang Y, Maidaiti X, Wu Y, Jin Y. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021. Sci Rep. 2024;14:22232. https:\/\/doi.org\/10.1038\/s41598-024-72795-0.","journal-title":"Sci Rep"},{"key":"2367_CR46","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jhep.2021.06.013","volume":"75","author":"X Chen","year":"2021","unstructured":"Chen X, Chen S, Pang J, Tang Y, Ling W. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol. 2021;75:987\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.013.","journal-title":"J Hepatol"},{"key":"2367_CR47","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48:1057\u201382. https:\/\/doi.org\/10.2337\/dci24-0094.","journal-title":"Diabetes Care"},{"key":"2367_CR48","doi-asserted-by":"publisher","first-page":"e0269265","DOI":"10.1371\/journal.pone.0269265","volume":"17","author":"R Bessho","year":"2022","unstructured":"Bessho R, Kashiwagi K, Ikura A, Yamataka K, Inaishi J, Takaishi H, et al. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS ONE. 2022;17:e0269265. https:\/\/doi.org\/10.1371\/journal.pone.0269265.","journal-title":"PLoS ONE"},{"key":"2367_CR49","doi-asserted-by":"publisher","first-page":"101326","DOI":"10.1016\/j.ajpc.2025.101326","volume":"24","author":"P Fallahtafti","year":"2025","unstructured":"Fallahtafti P, Soleimani H, Khanmohammadi S, Habibzadeh A, Taebi M, Azarboo A, et al. Global trends in cardiovascular mortality attributable to high body mass index: 1990\u20132021 analysis with future projections. Am J Prev Cardiol. 2025;24:101326. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101326.","journal-title":"Am J Prev Cardiol"},{"key":"2367_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","volume":"3","author":"SS Khan","year":"2018","unstructured":"Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol. 2018;3:280\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2018.0022.","journal-title":"JAMA Cardiol"},{"issue":"34","key":"2367_CR51","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1093\/eurheartj\/ehab454","volume":"42","author":"MS Kim","year":"2021","unstructured":"Kim MS, Kim WJ, Khera AV, Kim JY, Yon DK, Lee S, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J. 2021;42(34):3388\u2013403. https:\/\/doi.org\/10.1093\/eurheartj\/ehab454.","journal-title":"Eur Heart J"},{"key":"2367_CR52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1186\/s12889-021-10911-9","volume":"21","author":"NB Armas Rojas","year":"2021","unstructured":"Armas Rojas NB, Lacey B, Soni M, Charles S, Carter J, Varona-P\u00e9rez P, et al. Body-mass index, blood pressure, diabetes and cardiovascular mortality in Cuba: prospective study of 146,556 participants. BMC Public Health. 2021;21:963. https:\/\/doi.org\/10.1186\/s12889-021-10911-9.","journal-title":"BMC Public Health"},{"key":"2367_CR53","doi-asserted-by":"publisher","first-page":"e1005","DOI":"10.1016\/S2468-2667(24)00043-4","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Yu W, Lv J, Sun D, Pei P, Du H, et al. Early adulthood BMI and cardiovascular disease: a prospective cohort study from the China Kadoorie Biobank. Lancet Public Health. 2024;9:e1005\u201313. https:\/\/doi.org\/10.1016\/S2468-2667(24)00043-4.","journal-title":"Lancet Public Health"},{"key":"2367_CR54","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41366-024-01710-4","volume":"49","author":"Z Qiu","year":"2025","unstructured":"Qiu Z, Liu Z, Zhang N, Fan F, Weng H, Zhang L, et al. Association between early age body mass index and the risk of adulthood cardiovascular diseases: a systematic review and meta-analysis. Int J Obes. 2025;49:766\u201375. https:\/\/doi.org\/10.1038\/s41366-024-01710-4.","journal-title":"Int J Obes"},{"key":"2367_CR55","doi-asserted-by":"publisher","first-page":"e023667","DOI":"10.1161\/JAHA.121.023667","volume":"11","author":"C Held","year":"2022","unstructured":"Held C, Hadziosmanovic N, Aylward PE, Hagstr\u00f6m E, Hochman JS, Stewart RAH, et al. Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease \u2013 A STABILITY Substudy. J Am Heart Assoc. 2022;11:e023667. https:\/\/doi.org\/10.1161\/JAHA.121.023667.","journal-title":"J Am Heart Assoc"},{"key":"2367_CR56","doi-asserted-by":"publisher","first-page":"030006052093282","DOI":"10.1177\/0300060520932820","volume":"48","author":"D Sun","year":"2020","unstructured":"Sun D, Li W, Zhang H, Li Y, Zhang Q. Inverted U-shaped relationship between body mass index and multivessel lesions in Chinese patients with myocardial infarction: a cross-sectional study. J Int Med Res. 2020;48:0300060520932820. https:\/\/doi.org\/10.1177\/0300060520932820.","journal-title":"J Int Med Res"},{"key":"2367_CR57","doi-asserted-by":"publisher","unstructured":"Nowak MM, Niemczyk M, Go\u0142\u0119biewski S, P\u0105czek L. Impact of Body Mass Index on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(8):2305. https:\/\/doi.org\/10.3390\/jcm13082305.","DOI":"10.3390\/jcm13082305"},{"key":"2367_CR58","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","volume":"6","author":"K Bhaskaran","year":"2018","unstructured":"Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6:944\u201353. https:\/\/doi.org\/10.1016\/S2213-8587(18)30288-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2367_CR59","first-page":"454","volume":"3","author":"AH Abdelhafiz","year":"2012","unstructured":"Abdelhafiz AH, Loo BE, Hensey N, Bailey C, Sinclair A. The U-shaped Relationship of Traditional Cardiovascular Risk Factors and Adverse Outcomes in Later Life. Aging Disease. 2012;3:454\u201364.","journal-title":"Aging Disease"},{"key":"2367_CR60","doi-asserted-by":"publisher","first-page":"e0185024","DOI":"10.1371\/journal.pone.0185024","volume":"12","author":"KA Kong","year":"2017","unstructured":"Kong KA, Park J, Hong S-H, Hong YS, Sung Y-A, Lee H. Associations between body mass index and mortality or cardiovascular events in a general Korean population. PLoS ONE. 2017;12:e0185024. https:\/\/doi.org\/10.1371\/journal.pone.0185024.","journal-title":"PLoS ONE"},{"key":"2367_CR61","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.18632\/aging.202543","volume":"13","author":"J Hu","year":"2021","unstructured":"Hu J, Xu H, Zhu J, Zhang J, Li J, Chen L, et al. Association between body mass index and risk of cardiovascular disease-specific mortality among adults with hypertension in Shanghai, China. Aging. 2021;13:6866\u201377. https:\/\/doi.org\/10.18632\/aging.202543.","journal-title":"Aging"},{"key":"2367_CR62","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","volume":"143","author":"AG Doumouras","year":"2021","unstructured":"Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-E, et al. Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:: A Population-Based Retrospective Cohort Study. Circulation. 2021;143:1468\u201380. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052386.","journal-title":"Circulation"},{"key":"2367_CR63","doi-asserted-by":"publisher","unstructured":"Rao Z, Wang K, Zhou K, Duan Y, Zhang Y. Global burden and epidemic trends of chronic kidney disease attributable to high body mass index: insights from the Global Burden of Disease Study 2021. Ren Fail. 47:2512400. https:\/\/doi.org\/10.1080\/0886022X.2025.2512400","DOI":"10.1080\/0886022X.2025.2512400"},{"key":"2367_CR64","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.kint.2016.12.013","volume":"91","author":"C Garofalo","year":"2017","unstructured":"Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91:1224\u201335. https:\/\/doi.org\/10.1016\/j.kint.2016.12.013.","journal-title":"Kidney Int"},{"key":"2367_CR65","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1681\/ASN.2012070675","volume":"24","author":"RJ Silverwood","year":"2013","unstructured":"Silverwood RJ, Pierce M, Thomas C, Hardy R, Ferro C, Sattar N, et al. Association between younger age when first overweight and increased risk for CKD. J Am Soc Nephrol. 2013;24:813\u201321. https:\/\/doi.org\/10.1681\/ASN.2012070675.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2367_CR66","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2213-8587(15)00128-X","volume":"3","author":"JL Lu","year":"2015","unstructured":"Lu JL, Molnar MZ, Naseer A, Mikkelsen MK, Kalantar-Zadeh K, Kovesdy CP. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 2015;3(9):704\u201314. https:\/\/doi.org\/10.1016\/S2213-8587(15)00128-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2367_CR67","doi-asserted-by":"publisher","first-page":"k5301","DOI":"10.1136\/bmj.k5301","volume":"364","author":"AR Chang","year":"2019","unstructured":"Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301. https:\/\/doi.org\/10.1136\/bmj.k5301.","journal-title":"BMJ"},{"key":"2367_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.ajkd.2021.05.008","volume":"79","author":"J Wang","year":"2022","unstructured":"Wang J, Niratharakumar K, Gokhale K, Tahrani AA, Taverner T, Thomas GN, et al. Obesity Without Metabolic Abnormality and Incident CKD: A Population-Based British Cohort Study. Am J Kidney Dis. 2022;79:24\u2013e351. https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.008.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2367_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000437277","volume":"6","author":"SF Ahmadi","year":"2015","unstructured":"Ahmadi SF, Zahmatkesh G, Ahmadi E, et al. Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2015;6(1):37\u201349. https:\/\/doi.org\/10.1159\/000437277.","journal-title":"Cardiorenal Med"},{"key":"2367_CR70","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/ndt\/gfw075","volume":"32","author":"M Ladhani","year":"2017","unstructured":"Ladhani M, Craig JC, Irving M, Clayton PA, Wong G. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transpl. 2017;32:439\u201349. https:\/\/doi.org\/10.1093\/ndt\/gfw075.","journal-title":"Nephrol Dial Transpl"},{"key":"2367_CR71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.jrn.2017.01.016","volume":"27","author":"M Rahimlu","year":"2017","unstructured":"Rahimlu M, Shab-Bidar S, Djafarian K. Body Mass Index and All-cause Mortality in Chronic Kidney Disease: A Dose\u2013response Meta-analysis of Observational Studies. J Ren Nutr. 2017;27:225\u201332. https:\/\/doi.org\/10.1053\/j.jrn.2017.01.016.","journal-title":"J Ren Nutr"},{"key":"2367_CR72","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/ki.2014.384","volume":"87","author":"B Panwar","year":"2015","unstructured":"Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2015;87:1216\u201322. https:\/\/doi.org\/10.1038\/ki.2014.384.","journal-title":"Kidney Int"},{"key":"2367_CR73","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ndt\/gfad214","volume":"39","author":"SY Kang","year":"2024","unstructured":"Kang SY, Lee YH, Jeong SJ, Kim JS, Jeong KH, Hwang HS. How obesity and metabolic syndrome affect cardiovascular events, progression to kidney failure and all-cause mortality in chronic kidney disease. Nephrol Dial Transpl. 2024;39:778\u201387. https:\/\/doi.org\/10.1093\/ndt\/gfad214.","journal-title":"Nephrol Dial Transpl"},{"key":"2367_CR74","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","volume":"1","author":"S Albhaisi","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1:329\u201341. https:\/\/doi.org\/10.1016\/j.jhepr.2019.08.002.","journal-title":"JHEP Rep"},{"key":"2367_CR75","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2022.06.029","volume":"21","author":"A Tang","year":"2023","unstructured":"Tang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, et al. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21:1750\u2013e176012. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.029.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2367_CR76","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/hep4.1534","volume":"4","author":"P Golabi","year":"2020","unstructured":"Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun. 2020;4:1136\u201348. https:\/\/doi.org\/10.1002\/hep4.1534.","journal-title":"Hepatol Commun"},{"key":"2367_CR77","doi-asserted-by":"publisher","first-page":"e0241770","DOI":"10.1371\/journal.pone.0241770","volume":"15","author":"S Hirose","year":"2020","unstructured":"Hirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, et al. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS ONE. 2020;15:e0241770. https:\/\/doi.org\/10.1371\/journal.pone.0241770.","journal-title":"PLoS ONE"},{"key":"2367_CR78","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2021.07.016","volume":"20","author":"OT Ahmed","year":"2022","unstructured":"Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol. 2022;20:1374\u2013e13816. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2367_CR79","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/hep4.1818","volume":"6","author":"A Arvind","year":"2022","unstructured":"Arvind A, Henson JB, Osganian SA, Nath C, Steinhagen LM, Memel ZN, et al. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2022;6:309. https:\/\/doi.org\/10.1002\/hep4.1818.","journal-title":"Hepatol Commun"},{"key":"2367_CR80","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/gutjnl-2020-322564","volume":"71","author":"R Younes","year":"2022","unstructured":"Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71:382\u201390. https:\/\/doi.org\/10.1136\/gutjnl-2020-322564.","journal-title":"Gut"},{"key":"2367_CR81","doi-asserted-by":"publisher","first-page":"275","DOI":"10.14218\/JCTH.2019.00029","volume":"7","author":"IB Curcic","year":"2019","unstructured":"Curcic IB, Berkovic MC, Kuna L, Roguljic H, Smolic R, Varzic SC, et al. Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing? J Clin Transl Hepatol. 2019;7:275\u20139. https:\/\/doi.org\/10.14218\/JCTH.2019.00029.","journal-title":"J Clin Transl Hepatol"},{"key":"2367_CR82","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1002\/hep4.2081","volume":"6","author":"Y Lan","year":"2022","unstructured":"Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y, et al. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. Hepatol Commun. 2022;6:3393. https:\/\/doi.org\/10.1002\/hep4.2081.","journal-title":"Hepatol Commun"},{"key":"2367_CR83","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/joim.13069","volume":"288","author":"B Zou","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999\u20132016. J Intern Med. 2020;288:139\u201351. https:\/\/doi.org\/10.1111\/joim.13069.","journal-title":"J Intern Med"},{"issue":"3","key":"2367_CR84","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/j.aohep.2024.101288","volume":"29","author":"W Wongtrakul","year":"2024","unstructured":"Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis. Ann Hepatol. 2024;29(3):101288. https:\/\/doi.org\/10.1016\/j.aohep.2024.101288.","journal-title":"Ann Hepatol"},{"key":"2367_CR85","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995\u20132040. Hepatol Int. 2021;15:366\u201379. https:\/\/doi.org\/10.1007\/s12072-021-10143-4.","journal-title":"Hepatol Int"},{"key":"2367_CR86","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/apt.17424","volume":"57","author":"K Wijarnpreecha","year":"2023","unstructured":"Wijarnpreecha K, Li F, Lundin SK, Suresh D, Song MW, Tao C, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023;57:1014\u201327. https:\/\/doi.org\/10.1111\/apt.17424.","journal-title":"Aliment Pharmacol Ther"},{"key":"2367_CR87","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep4.1124","volume":"2","author":"H Hagstr\u00f6m","year":"2018","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2018;2:48\u201357. https:\/\/doi.org\/10.1002\/hep4.1124.","journal-title":"Hepatol Commun"},{"key":"2367_CR88","doi-asserted-by":"publisher","first-page":"366","DOI":"10.15403\/jgld-3622","volume":"30","author":"A Feldman","year":"2021","unstructured":"Feldman A, Wernly B, Strebinger G, Eder SK, Zandanell S, Niederseer D, et al. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects. J Gastrointestin Liver Dis. 2021;30:366\u201373. https:\/\/doi.org\/10.15403\/jgld-3622.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"2367_CR89","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(14)63307-2","volume":"146","author":"ACD Dela Cruz","year":"2014","unstructured":"Dela Cruz ACD, Bugianesi E, George J, Day CP, Liaquat HB, Charatcharoenwitthaya P, et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(5):S\u2013909. https:\/\/doi.org\/10.1016\/S0016-5085(14)63307-2.","journal-title":"Gastroenterology"},{"key":"2367_CR90","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5009\/gnl210084","volume":"16","author":"Y Kim","year":"2022","unstructured":"Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut Liver. 2022;16:290\u20139. https:\/\/doi.org\/10.5009\/gnl210084.","journal-title":"Gut Liver"},{"key":"2367_CR91","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee Y-H, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19:2138\u2013e214710. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2367_CR92","doi-asserted-by":"publisher","first-page":"11320","DOI":"10.1038\/s41598-024-61896-5","volume":"14","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zeng Y, Yang S, Ye C, Wang M, Peng T, et al. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals. Sci Rep. 2024;14:11320. https:\/\/doi.org\/10.1038\/s41598-024-61896-5.","journal-title":"Sci Rep"},{"key":"2367_CR93","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","volume":"21","author":"GE Chung","year":"2023","unstructured":"Chung GE, Yu SJ, Yoo J-J, Cho Y, Lee K, Shin DW, et al. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. BMC Med. 2023;21:4. https:\/\/doi.org\/10.1186\/s12916-022-02716-3.","journal-title":"BMC Med"},{"key":"2367_CR94","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ijcard.2016.10.106","volume":"227","author":"P Liao","year":"2017","unstructured":"Liao P, Zeng R, Zhao X, Guo L, Zhang M. Prognostic value of non-high-density lipoprotein cholesterol for mortality in patients with coronary heart disease: A systematic review and meta-analysis. Int J Cardiol. 2017;227:950\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.106.","journal-title":"Int J Cardiol"},{"key":"2367_CR95","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302\u20139. https:\/\/doi.org\/10.1001\/jama.2012.366.","journal-title":"JAMA"},{"key":"2367_CR96","doi-asserted-by":"publisher","first-page":"1591705","DOI":"10.3389\/fnut.2025.1591705","volume":"12","author":"Z Fu","year":"2025","unstructured":"Fu Z, Zhang W, Li S. Non-HDL-C and age-stratified mortality risk in the US general population: a population-based cohort study. Front Nutr. 2025;12:1591705. https:\/\/doi.org\/10.3389\/fnut.2025.1591705.","journal-title":"Front Nutr"},{"key":"2367_CR97","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3343\/alm.2023.43.3.221","volume":"43","author":"Y-M Yun","year":"2023","unstructured":"Yun Y-M, Apolipoprotein B, Non -HDL, Cholesterol, LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment. Ann Lab Med. 2023;43:221\u20132. https:\/\/doi.org\/10.3343\/alm.2023.43.3.221.","journal-title":"Ann Lab Med"},{"key":"2367_CR98","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/MOL.0000000000000237","volume":"26","author":"R Verbeek","year":"2015","unstructured":"Verbeek R, Hovingh GK, Boekholdt SM. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol. 2015;26:502\u201310. https:\/\/doi.org\/10.1097\/MOL.0000000000000237.","journal-title":"Curr Opin Lipidol"},{"key":"2367_CR99","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","volume":"394","author":"FJ Brunner","year":"2019","unstructured":"Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394:2173\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(19)32519-X.","journal-title":"Lancet"},{"key":"2367_CR100","doi-asserted-by":"publisher","first-page":"100774","DOI":"10.1016\/j.lanepe.2023.100774","volume":"36","author":"MK Hansen","year":"2023","unstructured":"Hansen MK, Mortensen MB, Olesen KKW, Thrane PG, Maeng M. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. Lancet Reg Health Eur. 2023;36:100774. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100774.","journal-title":"Lancet Reg Health Eur"},{"key":"2367_CR101","doi-asserted-by":"publisher","first-page":"1065750","DOI":"10.3389\/fcvm.2023.1065750","volume":"10","author":"Y Huang","year":"2023","unstructured":"Huang Y, Yan MQ, Zhou D, Chen CL, Feng YQ. The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. Front Cardiovasc Med. 2023;10:1065750. https:\/\/doi.org\/10.3389\/fcvm.2023.1065750.","journal-title":"Front Cardiovasc Med"},{"key":"2367_CR102","doi-asserted-by":"publisher","first-page":"903481","DOI":"10.3389\/fcvm.2022.903481","volume":"9","author":"RX Zeng","year":"2022","unstructured":"Zeng RX, Xu JP, Kong YJ, Tan JW, Guo LH, Zhang MZ. U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy. Front Cardiovasc Med. 2022;9:903481. https:\/\/doi.org\/10.3389\/fcvm.2022.903481.","journal-title":"Front Cardiovasc Med"},{"key":"2367_CR103","doi-asserted-by":"publisher","first-page":"707701","DOI":"10.3389\/fcvm.2021.707701","volume":"8","author":"Q Cheng","year":"2021","unstructured":"Cheng Q, Liu X-C, Chen C-L, Huang Y-Q, Feng Y-Q, Chen J-Y. The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension. Front Cardiovasc Med. 2021;8:707701. https:\/\/doi.org\/10.3389\/fcvm.2021.707701.","journal-title":"Front Cardiovasc Med"},{"key":"2367_CR104","doi-asserted-by":"publisher","first-page":"12749","DOI":"10.1038\/s41598-020-69794-2","volume":"10","author":"H Chiu","year":"2020","unstructured":"Chiu H, Wu P-Y, Huang J-C, Tu H-P, Lin M-Y, Chen S-C, et al. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3\u20135. Sci Rep. 2020;10:12749. https:\/\/doi.org\/10.1038\/s41598-020-69794-2.","journal-title":"Sci Rep"},{"key":"2367_CR105","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/nu14183792","volume":"14","author":"SH Suh","year":"2022","unstructured":"Suh SH, Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, et al. Non-High-Density Lipoprotein Cholesterol and Cardiovascular Outcomes in Chronic Kidney Disease: Results from KNOW-CKD Study. Nutrients. 2022;14:3792. https:\/\/doi.org\/10.3390\/nu14183792.","journal-title":"Nutrients"},{"key":"2367_CR106","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jacl.2019.08.001","volume":"13","author":"M Soohoo","year":"2019","unstructured":"Soohoo M, Moradi H, Obi Y, Kovesdy CP, Kalantar-Zadeh K, Streja E. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. J Clin Lipidol. 2019;13:744\u2013e75315. https:\/\/doi.org\/10.1016\/j.jacl.2019.08.001.","journal-title":"J Clin Lipidol"},{"key":"2367_CR107","doi-asserted-by":"publisher","first-page":"e009096","DOI":"10.1161\/JAHA.118.009096","volume":"7","author":"TI Chang","year":"2018","unstructured":"Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, et al. Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. J Am Heart Assoc. 2018;7:e009096. https:\/\/doi.org\/10.1161\/JAHA.118.009096.","journal-title":"J Am Heart Assoc"},{"key":"2367_CR108","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jacl.2018.03.085","volume":"12","author":"SD Navaneethan","year":"2018","unstructured":"Navaneethan SD, Schold JD, Walther CP, Arrigain S, Jolly SE, Virani SS, et al. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018;12:1061\u2013e10717. https:\/\/doi.org\/10.1016\/j.jacl.2018.03.085.","journal-title":"J Clin Lipidol"},{"key":"2367_CR109","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.jrn.2013.01.022","volume":"23","author":"H Moradi","year":"2013","unstructured":"Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K. Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J Ren Nutr. 2013;23:203\u20136. https:\/\/doi.org\/10.1053\/j.jrn.2013.01.022.","journal-title":"J Ren Nutr"},{"key":"2367_CR110","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.jacc.2012.09.013","volume":"60","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012;60:2372\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.013.","journal-title":"J Am Coll Cardiol"},{"key":"2367_CR111","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"W Collaboration, Herrington","year":"2016","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT), Collaboration, Herrington W, Emberson J, Mihaylova B, Blackwell L, Reith C, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829\u201339. https:\/\/doi.org\/10.1016\/S2213-8587(16)30156-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2367_CR112","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","volume":"178","author":"M Madero","year":"2025","unstructured":"Madero M, Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, et al. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline. Ann Intern Med. 2025;178(5):705\u201313. https:\/\/doi.org\/10.7326\/ANNALS-24-01926.","journal-title":"Ann Intern Med"},{"key":"2367_CR113","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12986-025-00942-z","volume":"22","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Luo P-Y, Tang Y-N, Wang J, Gao S, Fan Y-C, et al. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): data from the NHANES III (1988\u20131994). Nutr Metab. 2025;22:46. https:\/\/doi.org\/10.1186\/s12986-025-00942-z.","journal-title":"Nutr Metab"},{"key":"2367_CR114","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cgh.2012.01.017","volume":"10","author":"KE Corey","year":"2012","unstructured":"Corey KE, Lai M, Gelrud LG, Misdraji J, Barlow LL, Zheng H, et al. Non\u2013High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2012;10:651\u20136. https:\/\/doi.org\/10.1016\/j.cgh.2012.01.017.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2367_CR115","doi-asserted-by":"publisher","first-page":"1457589","DOI":"10.3389\/fendo.2024.1457589","volume":"15","author":"Y Xuan","year":"2024","unstructured":"Xuan Y, Zhu M, Xu L, Huangfu S, Li T, Liu C, et al. Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis. Front Endocrinol. 2024;15:1457589. https:\/\/doi.org\/10.3389\/fendo.2024.1457589.","journal-title":"Front Endocrinol"},{"key":"2367_CR116","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1111\/liv.12318","volume":"34","author":"S Zelber-Sagi","year":"2014","unstructured":"Zelber-Sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int. 2014;34:e128\u2013135. https:\/\/doi.org\/10.1111\/liv.12318.","journal-title":"Liver Int"},{"key":"2367_CR117","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jama.2019.10298","volume":"322","author":"MS Duncan","year":"2019","unstructured":"Duncan MS, Freiberg MS, Greevy RA, Kundu S, Vasan RS, Tindle HA. Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease. JAMA. 2019;322:642\u201350. https:\/\/doi.org\/10.1001\/jama.2019.10298.","journal-title":"JAMA"},{"key":"2367_CR118","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/pubmed\/fdr025","volume":"33","author":"IP Oono","year":"2011","unstructured":"Oono IP, Mackay DF, Pell JP. Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health. 2011;33:496\u2013502. https:\/\/doi.org\/10.1093\/pubmed\/fdr025.","journal-title":"J Public Health"},{"key":"2367_CR119","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.115.017926","volume":"132","author":"A Pan","year":"2015","unstructured":"Pan A, Wang Y, Talaei M, Hu FB. Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review. Circulation. 2015;132:1795\u2013804. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017926.","journal-title":"Circulation"},{"key":"2367_CR120","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41100-024-00533-3","volume":"10","author":"SM Lang","year":"2024","unstructured":"Lang SM, Schiffl H. Smoking status, cadmium, and chronic kidney disease. Ren Replace Ther. 2024;10:17. https:\/\/doi.org\/10.1186\/s41100-024-00533-3.","journal-title":"Ren Replace Ther"},{"key":"2367_CR121","doi-asserted-by":"crossref","unstructured":"Lv T, Xu F, Li J, Sun D, Liu H, Qi H et al. The causal relationship between smoke and renal impairment: a two-sample Mendelian randomization and meta-analysis. Crit Public Health. 2025;35. https:\/\/api.semanticscholar.org\/CorpusID:279631333","DOI":"10.1080\/09581596.2025.2519775"},{"key":"2367_CR122","doi-asserted-by":"publisher","first-page":"870278","DOI":"10.3389\/fmed.2022.870278","volume":"9","author":"YC Fu","year":"2022","unstructured":"Fu YC, Xu ZL, Zhao MY, Xu K. The Association Between Smoking and Renal Function in People Over 20 Years Old. Front Med (Lausanne). 2022;9:870278. https:\/\/doi.org\/10.3389\/fmed.2022.870278.","journal-title":"Front Med (Lausanne)"},{"key":"2367_CR123","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ntr\/ntaa071","volume":"23","author":"S Lee","year":"2021","unstructured":"Lee S, Kang S, Joo YS, Lee C, Nam KH, Yun H-R, et al. Smoking, Smoking Cessation, and Progression of Chronic Kidney Disease: Results From KNOW-CKD Study. Nicotine Tob Res. 2021;23:92\u20138. https:\/\/doi.org\/10.1093\/ntr\/ntaa071.","journal-title":"Nicotine Tob Res"},{"key":"2367_CR124","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1186\/1471-2458-10-731","volume":"10","author":"R Yacoub","year":"2010","unstructured":"Yacoub R, Habib H, Lahdo A, Al Ali R, Varjabedian L, Atalla G, et al. Association between smoking and chronic kidney disease: a case control study. BMC Public Health. 2010;10:731. https:\/\/doi.org\/10.1186\/1471-2458-10-731.","journal-title":"BMC Public Health"},{"key":"2367_CR125","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2337\/diab.42.3.381","volume":"42","author":"R Klein","year":"1993","unstructured":"Klein R, Klein BE, Moss SE. Incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes. 1993;42:381\u20139. https:\/\/doi.org\/10.2337\/diab.42.3.381.","journal-title":"Diabetes"},{"issue":"1","key":"2367_CR126","doi-asserted-by":"publisher","first-page":"14778","DOI":"10.1038\/s41598-021-94270-w","volume":"11","author":"M Provenzano","year":"2021","unstructured":"Provenzano M, Serra R, Michael A, Bolignano D, Coppolino G, Ielapi N, et al. Smoking habit as a risk amplifier in chronic kidney disease patients. Sci Rep. 2021;11(1):14778. https:\/\/doi.org\/10.1038\/s41598-021-94270-w.","journal-title":"Sci Rep"},{"key":"2367_CR127","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2215\/CJN.11121017","volume":"13","author":"JD Bundy","year":"2018","unstructured":"Bundy JD, Bazzano LA, Xie D, Cohan J, Dolata J, Fink JC, et al. Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol. 2018;13:993\u20131001. https:\/\/doi.org\/10.2215\/CJN.11121017.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2367_CR128","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/cells14030221","volume":"14","author":"J Xu","year":"2025","unstructured":"Xu J, Li Y, Feng Z, Chen H. Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy. Cells. 2025;14:221. https:\/\/doi.org\/10.3390\/cells14030221.","journal-title":"Cells"},{"key":"2367_CR129","doi-asserted-by":"publisher","first-page":"396","DOI":"10.61336\/ejcm\/25-09-63","volume":"15","author":"DN Gajjar","year":"2025","unstructured":"Gajjar DN, Patel S, Shah DR, Shah GR, Patel AD, Patel VV. Comparative Analysis of Lipid Profiles in Young Smokers and Non-Smokers. Eur J Cardiovasc Med. 2025;15:396\u20139. https:\/\/doi.org\/10.61336\/ejcm\/25-09-63.","journal-title":"Eur J Cardiovasc Med"},{"key":"2367_CR130","doi-asserted-by":"publisher","unstructured":"Sousa IR, Miranda M, Gomes H, Figueiredo A, Silva J, Campos J. Relationship Between Smoking and Lipid Profile in Four Primary Health Care Units: A Research Study. Cureus 16:e69172. https:\/\/doi.org\/10.7759\/cureus.69172","DOI":"10.7759\/cureus.69172"},{"key":"2367_CR131","doi-asserted-by":"publisher","first-page":"1015919","DOI":"10.3389\/fpubh.2023.1015919","volume":"11","author":"YS Jang","year":"2023","unstructured":"Jang YS, Joo HJ, Park YS, Park E-C, Jang S-I. Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score. Front Public Health. 2023;11:1015919. https:\/\/doi.org\/10.3389\/fpubh.2023.1015919.","journal-title":"Front Public Health"},{"key":"2367_CR132","doi-asserted-by":"publisher","first-page":"e0300","DOI":"10.1097\/HC9.0000000000000300","volume":"7","author":"O Balogun","year":"2023","unstructured":"Balogun O, Wang JY, Shaikh ES, Liu K, Stoyanova S, Memel ZN, et al. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD. Hepatol Commun. 2023;7:e0300. https:\/\/doi.org\/10.1097\/HC9.0000000000000300.","journal-title":"Hepatol Commun"},{"issue":"1","key":"2367_CR133","doi-asserted-by":"publisher","first-page":"31029","DOI":"10.1038\/s41598-025-16750-7","volume":"15","author":"SH Cho","year":"2025","unstructured":"Cho SH, Kim G, Lee KN, Oh R, Kim JY, Jang M, et al. Impact of smoking and physical activity on cardiovascular outcomes in type 2 diabetes across steatotic liver disease categories. Sci Rep. 2025;15(1):31029. https:\/\/doi.org\/10.1038\/s41598-025-16750-7.","journal-title":"Sci Rep"},{"key":"2367_CR134","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s44324-025-00068-z","volume":"3","author":"P McLean","year":"2025","unstructured":"McLean P, Bennett J, Trey Woods E, Chandrasekhar S, Newman N, Mohammad Y, et al. SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach. npj Metab Health Dis. 2025;3:29. https:\/\/doi.org\/10.1038\/s44324-025-00068-z.","journal-title":"npj Metab Health Dis"},{"key":"2367_CR135","doi-asserted-by":"publisher","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","volume":"101","author":"G Ranjbar","year":"2019","unstructured":"Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism. 2019;101:154001. https:\/\/doi.org\/10.1016\/j.metabol.2019.154001.","journal-title":"Metabolism"},{"key":"2367_CR136","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025;86:103363. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103363.","journal-title":"eClinicalMedicine"},{"issue":"12","key":"2367_CR137","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"2367_CR138","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"2","key":"2367_CR139","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"2367_CR140","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","volume":"16","author":"M de Jong","year":"2017","unstructured":"de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16:134. https:\/\/doi.org\/10.1186\/s12933-017-0617-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2367_CR141","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","volume":"20","author":"L Nesti","year":"2021","unstructured":"Nesti L, Tric\u00f2 D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109. https:\/\/doi.org\/10.1186\/s12933-021-01294-7.","journal-title":"Cardiovasc Diabetol"},{"key":"2367_CR142","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.3390\/ijms21134725","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci. 2020;21:4725. https:\/\/doi.org\/10.3390\/ijms21134725.","journal-title":"Int J Mol Sci"},{"key":"2367_CR143","doi-asserted-by":"publisher","first-page":"2594355","DOI":"10.1080\/07853890.2025.2594355","volume":"57","author":"AS Albawa\u2019neh","year":"2025","unstructured":"Albawa\u2019neh AS, Alqasrawi MN, Al-Mahayri ZN, Albawaana A, Ahmed G, Al-Rifai RH, et al. Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis. Ann Med. 2025;57:2594355. https:\/\/doi.org\/10.1080\/07853890.2025.2594355.","journal-title":"Ann Med"},{"key":"2367_CR144","doi-asserted-by":"publisher","unstructured":"Fras Z, Mikhailidis DP. Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Curr Vasc Pharmacol 19:451\u201368. https:\/\/doi.org\/10.2174\/1570161118999200727224946","DOI":"10.2174\/1570161118999200727224946"},{"key":"2367_CR145","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","volume":"270","author":"TG Simon","year":"2018","unstructured":"Simon TG, Corey KE, Cannon CP, Blazing M, Park J-G, O\u2019Donoghue ML, et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018;270:245\u201352. https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.087.","journal-title":"Int J Cardiol"},{"key":"2367_CR146","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.3390\/jcm13133927","volume":"13","author":"D-E Sung","year":"2024","unstructured":"Sung D-E, Lee S-J, Lee M-Y, Rhee E-J, Sung K-C. Longitudinal Analysis of Diabetes Mellitus Risk: Smoking Status and Smoking Cessation. J Clin Med. 2024;13:3927. https:\/\/doi.org\/10.3390\/jcm13133927.","journal-title":"J Clin Med"},{"issue":"7","key":"2367_CR147","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1803626","volume":"379","author":"Y Hu","year":"2018","unstructured":"Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med. 2018;379(7):623\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1803626.","journal-title":"N Engl J Med"},{"key":"2367_CR148","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/ntr\/ntab076","volume":"23","author":"X Wang","year":"2021","unstructured":"Wang X, Qin L-Q, Arafa A, Eshak ES, Hu Y, Dong J-Y. Smoking Cessation, Weight Gain, Cardiovascular Risk, and All-Cause Mortality: A Meta-analysis. Nicotine Tob Res. 2021;23:1987\u201394. https:\/\/doi.org\/10.1093\/ntr\/ntab076.","journal-title":"Nicotine Tob Res"},{"key":"2367_CR149","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/0115701611340703240809044916","volume":"23","author":"S Borozan","year":"2025","unstructured":"Borozan S, Vujosevic S, Mikhailidis DP, Muzurovic E. Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful? Curr Vasc Pharmacol. 2025;23:4\u20137. https:\/\/doi.org\/10.2174\/0115701611340703240809044916.","journal-title":"Curr Vasc Pharmacol"},{"key":"2367_CR150","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/011871529X345190241113103911","volume":"24","author":"T Biswas","year":"2024","unstructured":"Biswas T, Lehker A, Mukherjee D. Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction. Cardiovasc Hematol Disord Drug Targets. 2024;24:211\u20137. https:\/\/doi.org\/10.2174\/011871529X345190241113103911.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"5","key":"2367_CR151","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/1570161114666160722112738","volume":"14","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Athyros VG, Mikhailidis DP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: An underestimated predictor of vascular risk? Curr Vasc Pharmacol. 2016;14(5):432\u201341. https:\/\/doi.org\/10.2174\/1570161114666160722112738.","journal-title":"Curr Vasc Pharmacol"},{"key":"2367_CR152","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/0003319718776528","volume":"69","author":"N Katsiki","year":"2018","unstructured":"Katsiki N, Mikhailidis DP. Abnormal Peri-Organ or Intra-Organ Fat Deposition and Vascular Risk. Angiology. 2018;69:841\u20132. https:\/\/doi.org\/10.1177\/0003319718776528.","journal-title":"Angiology"},{"key":"2367_CR153","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14744\/AnatolJCardiol.2016.6885","volume":"17","author":"SA Kocaman","year":"2017","unstructured":"Kocaman SA, Baysan O, \u00c7etin M, Altuner TK, Ocakl\u0131 EP, Durako\u011flugil ME, et al. An increase in epicardial adipose tissue is strongly associated with carotid intima-media thickness and atherosclerotic plaque, but LDL only with the plaque. Anatol J Cardiol. 2017;17:56\u201363. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2016.6885.","journal-title":"Anatol J Cardiol"},{"key":"2367_CR154","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12933-024-02399-5","volume":"23","author":"CM Perdomo","year":"2024","unstructured":"Perdomo CM, Martin-Calvo N, Ezponda A, Mendoza FJ, Bastarrika G, Garcia-Fernandez N, et al. Epicardial and liver fat implications in albuminuria: a retrospective study. Cardiovasc Diabetol. 2024;23:308. https:\/\/doi.org\/10.1186\/s12933-024-02399-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2367_CR155","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/joim.12344","volume":"278","author":"AC Cordeiro","year":"2015","unstructured":"Cordeiro AC, Amparo FC, Oliveira MA, Amodeo C, Smanio P, Pinto I, et al. Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3\u20135 chronic kidney disease. J Intern Med. 2015;278(1):77\u201387. https:\/\/doi.org\/10.1111\/joim.12344.","journal-title":"J Intern Med"},{"issue":"1","key":"2367_CR156","first-page":"64","volume":"17","author":"N Katsiki","year":"2017","unstructured":"Katsiki N, Mikhailidis DP. Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice? Anatol J Cardiol. 2017;17(1):64\u20135. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5324865\/.","journal-title":"Anatol J Cardiol"},{"issue":"5","key":"2367_CR157","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/10742484211006997","volume":"26","author":"EM Muzurovi\u0107","year":"2021","unstructured":"Muzurovi\u0107 EM, Vujo\u0161evi\u0107 S, Mikhailidis DP. Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes? J Cardiovasc Pharmacol Ther. 2021;26(5):415\u201336. https:\/\/doi.org\/10.1177\/10742484211006997.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"2367_CR158","doi-asserted-by":"publisher","first-page":"997","DOI":"10.5114\/aoms\/189575","volume":"20","author":"T Jamialahmadi","year":"2024","unstructured":"Jamialahmadi T, Simental-Mendia LE, Eid AH, Almahmeed W, Salehabadi S, Al-Rasadi K, et al. Efficacy of statin therapy in reducing epicardial adipose tissue: a systematic review and meta-analysis. Arch Med Sci. 2024;20(3):997\u20131001. https:\/\/doi.org\/10.5114\/aoms\/189575.","journal-title":"Arch Med Sci"},{"key":"2367_CR159","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10620-021-06824-7","volume":"67","author":"TD Filippatos","year":"2022","unstructured":"Filippatos TD, Alexakis K, Mavrikaki V, Mikhailidis DP, Prediabetes. Diabetes Atherosclerosis Dig Dis Sci. 2022;67:26\u201341. https:\/\/doi.org\/10.1007\/s10620-021-06824-7.","journal-title":"Diabetes Atherosclerosis Dig Dis Sci"},{"issue":"7","key":"2367_CR160","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/0003319719848204","volume":"70","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal adiposity and other excessive intra- and peri-organ fat depots: what is the connection? Angiology. 2019;70(7):581\u20133. https:\/\/doi.org\/10.1177\/0003319719848204.","journal-title":"Angiology"},{"key":"2367_CR161","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4330\/wjc.v16.i10.580","volume":"16","author":"S Cernea","year":"2024","unstructured":"Cernea S, Oni\u0219or D, Roiban AL, Benedek T, Rat N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World J Cardiol. 2024;16:580\u201394. https:\/\/doi.org\/10.4330\/wjc.v16.i10.580.","journal-title":"World J Cardiol"},{"key":"2367_CR162","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/00365521.2025.2536585","volume":"60","author":"B Ismail","year":"2025","unstructured":"Ismail B, Nabilou P, Gluud LL, M\u00f8ller S. Cardiovascular implications of MASLD: overview of the evidence. Medline Abbreviated Title: Scand J Gastroenterol. 2025;60:910\u20138. https:\/\/doi.org\/10.1080\/00365521.2025.2536585.","journal-title":"Medline Abbreviated Title: Scand J Gastroenterol"},{"key":"2367_CR163","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","volume":"79","author":"E Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 E, Peng CC-H, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension. 2022;79:1319\u201326. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.17982.","journal-title":"Hypertension"},{"key":"2367_CR164","doi-asserted-by":"publisher","first-page":"154770","DOI":"10.1016\/j.metabol.2021.154770","volume":"119","author":"E Muzurovi\u0107","year":"2021","unstructured":"Muzurovi\u0107 E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770. https:\/\/doi.org\/10.1016\/j.metabol.2021.154770.","journal-title":"Metabolism"},{"key":"2367_CR165","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.21037\/atm.2019.12.153","volume":"8","author":"N Katsiki","year":"2020","unstructured":"Katsiki N, Mikhailidis DP. Diabetes and carotid artery disease: a narrative review. Ann Transl Med. 2020;8:1280. https:\/\/doi.org\/10.21037\/atm.2019.12.153.","journal-title":"Ann Transl Med"},{"key":"2367_CR166","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1177\/0003319718755581","volume":"69","author":"E Randrianarisoa","year":"2018","unstructured":"Randrianarisoa E, Stefan N, Fritsche A, Reis-Damaschk N, Hieronimus A, Balletshofer B, et al. Periaortic Adipose Tissue Compared With Peribrachial Adipose Tissue Mass as Markers and Possible Modulators of Cardiometabolic Risk. Angiology. 2018;69:854\u201360. https:\/\/doi.org\/10.1177\/0003319718755581.","journal-title":"Angiology"},{"key":"2367_CR167","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","volume":"76","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis M, Muzurovi\u0107 E, Vol\u010dan\u0161ek \u0160, Chakhtoura M, Hill MA, Mikhailidis DP, et al. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacol Rev. 2024;76:454\u201399. https:\/\/doi.org\/10.1124\/pharmrev.123.001087.","journal-title":"Pharmacol Rev"},{"key":"2367_CR168","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128378484250619080753","author":"E Muzurovi\u0107","year":"2025","unstructured":"Muzurovi\u0107 E, Haluzik M, Horv\u00e1th L, Vlacho B, Mauricio D. Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease. Curr Pharm Des. 2025. https:\/\/doi.org\/10.2174\/0113816128378484250619080753.","journal-title":"Curr Pharm Des"},{"key":"2367_CR169","doi-asserted-by":"publisher","first-page":"107424842311868","DOI":"10.1177\/10742484231186855","volume":"28","author":"RV Giglio","year":"2023","unstructured":"Giglio RV, Muzurovi\u0107 EM, Patti AM, Toth PP, Agarwal MA, Almahmeed W, et al. Treatment with Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? J Cardiovasc Pharmacol Ther. 2023;28:10742484231186855. https:\/\/doi.org\/10.1177\/10742484231186855.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2367_CR170","doi-asserted-by":"publisher","first-page":"154305","DOI":"10.1016\/j.metabol.2020.154305","volume":"109","author":"E Muzurovi\u0107","year":"2020","unstructured":"Muzurovi\u0107 E, Mikhailidis DP, Mantzoros C, Commentary. From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism. 2020;109:154305. https:\/\/doi.org\/10.1016\/j.metabol.2020.154305.","journal-title":"Metabolism"},{"key":"2367_CR171","doi-asserted-by":"publisher","first-page":"108359","DOI":"10.1016\/j.jdiacomp.2022.108359","volume":"36","author":"E Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 E, Rizzo M, Mikhailidis DP. Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients. J Diabetes Complications. 2022;36:108359. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108359.","journal-title":"J Diabetes Complications"},{"key":"2367_CR172","doi-asserted-by":"publisher","first-page":"156494","DOI":"10.1016\/j.metabol.2026.156494","volume":"177","author":"E Muzurovi\u0107","year":"2026","unstructured":"Muzurovi\u0107 E, Katsiki N, Vol\u010dan\u0161ek \u0160, Plescia F, Rizzo M, Mantzoros CS. Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494. https:\/\/doi.org\/10.1016\/j.metabol.2026.156494.","journal-title":"Metabolism"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02367-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02367-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02367-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:14:25Z","timestamp":1776064465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02367-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":172,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02367-3","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}